首页 > 最新文献

Journal of cancer research and therapeutics最新文献

英文 中文
Myxoid liposarcoma diagnosed on fine needle aspiration cytology: There is more to it than meets the eye. 细针穿刺细胞学诊断为肌样脂肪肉瘤:它比我们看到的要复杂得多。
Pub Date : 2024-07-17 DOI: 10.4103/jcrt.jcrt_419_24
Md Ali Osama, Priti Chatterjee, Smita Singh, Ankita Pandey, Anup Mohta

Abstract: Liposarcoma is a rare mesenchymal neoplasm commonly involving deep soft tissues and the retroperitoneum. Among the various types of liposarcoma, myxoid liposarcoma is the most frequently encountered in adolescents and young adults, with a predilection for lower extremities. Fine needle aspiration allows easy assessment and rapid on-site evaluation for distinguishing benign from malignant lipomatous lesions. Here, we present a case of myxoid liposarcoma in the calf region of a 19-year-old boy, diagnosed via fine needle aspiration cytology, and subsequently confirmed by histopathological examination after surgical resection. The intention behind this case report is to highlight the cytological features of myxoid liposarcoma and to improve understanding of this tumor entity, aiming to prevent misdiagnosis by inexperienced pathologists when evaluating cytology specimens.

摘要:脂肪肉瘤是一种罕见的间叶肿瘤,通常累及深部软组织和腹膜后。在各种类型的脂肪肉瘤中,肌样脂肪肉瘤最常见于青少年和年轻成年人,且好发于下肢。细针穿刺术便于评估和现场快速评价,可区分良性和恶性脂肪瘤病变。在此,我们介绍了一例 19 岁男孩小腿部位的类肌脂肪肉瘤病例,该病例通过细针穿刺细胞学检查确诊,随后在手术切除后经组织病理学检查确诊。本病例报告旨在强调肌样脂肪肉瘤的细胞学特征,加深人们对这一肿瘤实体的认识,从而避免经验不足的病理学家在评估细胞学标本时误诊。
{"title":"Myxoid liposarcoma diagnosed on fine needle aspiration cytology: There is more to it than meets the eye.","authors":"Md Ali Osama, Priti Chatterjee, Smita Singh, Ankita Pandey, Anup Mohta","doi":"10.4103/jcrt.jcrt_419_24","DOIUrl":"10.4103/jcrt.jcrt_419_24","url":null,"abstract":"<p><strong>Abstract: </strong>Liposarcoma is a rare mesenchymal neoplasm commonly involving deep soft tissues and the retroperitoneum. Among the various types of liposarcoma, myxoid liposarcoma is the most frequently encountered in adolescents and young adults, with a predilection for lower extremities. Fine needle aspiration allows easy assessment and rapid on-site evaluation for distinguishing benign from malignant lipomatous lesions. Here, we present a case of myxoid liposarcoma in the calf region of a 19-year-old boy, diagnosed via fine needle aspiration cytology, and subsequently confirmed by histopathological examination after surgical resection. The intention behind this case report is to highlight the cytological features of myxoid liposarcoma and to improve understanding of this tumor entity, aiming to prevent misdiagnosis by inexperienced pathologists when evaluating cytology specimens.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A prospective study of circulating estrogen in oral leukoplakia and oral squamous cell carcinoma. 口腔白斑和口腔鳞状细胞癌中循环雌激素的前瞻性研究。
Pub Date : 2024-07-01 Epub Date: 2023-12-15 DOI: 10.4103/jcrt.jcrt_2377_22
Eesha Thakare, Minal Chaudhary, Amol Gadbail

Background: Reports suggested that hormone replacement therapy decreased the incidence of squamous cell carcinoma (SCC) of the oral cavity.

Aim: The aim of this study was to analyze and quantify the serum 17β-estradiol (E2) level by chemiluminescence immunoassay in four groups, Group I (control group with no habit of tobacco and areca), Group II (control group with a habit of tobacco and areca), Group III (potentially malignant disorder-leukoplakia), and Group IV (oral squamous cell carcinoma (OSCC)). It was the first study to evaluate E2 in four study groups with and without the habit of tobacco.

Method: The serum analysis was carried out in Cobas e411 analyzer by electrochemiluminescence immunoassay analysis.

Results: As per the Kruskal--Wallis test, statistically significant rise in estradiol levels in Group IV as in comparison to Group III as compared with Groups II and I.

Conclusion: This study proved that irrespective of the gender bias, the female sex hormone, estradiol levels were significantly raised in OSCC patients. This study suggests that E2 may play a vital role in determining the patient prognosis in OSCC with tobacco habit. The confounding results of this preliminary study opened up new advents emphasizing the role of E2 in OSCC. The role of E2 in estrogen receptor regulation can also be a subject of study for targeted therapies in improving the patient's prognosis.

背景:有报道称,激素替代疗法可降低口腔鳞状细胞癌(SCC)的发病率。目的:本研究旨在通过化学发光免疫测定法分析和量化四组人群的血清 17β-雌二醇(E2)水平,这四组人群分别是:I 组(无烟草和咀嚼习惯的对照组)、II 组(有烟草和咀嚼习惯的对照组)、III 组(潜在恶性疾病-白斑病)和 IV 组(口腔鳞状细胞癌(OSCC))。这是首次对有烟草习惯和无烟草习惯的四个研究组的 E2 进行评估的研究:血清分析在 Cobas e411 分析仪上通过电化学发光免疫分析法进行:结果:根据Kruskal--Wallis检验,与II组和I组相比,IV组的雌二醇水平与III组相比有统计学意义的上升:本研究证明,无论性别如何,OSCC 患者体内的女性性激素雌二醇水平均明显升高。这项研究表明,雌二醇在决定有吸烟习惯的 OSCC 患者的预后方面可能起着至关重要的作用。这项初步研究的干扰性结果为强调 E2 在 OSCC 中的作用开辟了新的思路。E2在雌激素受体调控中的作用也可作为靶向疗法的研究课题,以改善患者的预后。
{"title":"A prospective study of circulating estrogen in oral leukoplakia and oral squamous cell carcinoma.","authors":"Eesha Thakare, Minal Chaudhary, Amol Gadbail","doi":"10.4103/jcrt.jcrt_2377_22","DOIUrl":"10.4103/jcrt.jcrt_2377_22","url":null,"abstract":"<p><strong>Background: </strong>Reports suggested that hormone replacement therapy decreased the incidence of squamous cell carcinoma (SCC) of the oral cavity.</p><p><strong>Aim: </strong>The aim of this study was to analyze and quantify the serum 17β-estradiol (E2) level by chemiluminescence immunoassay in four groups, Group I (control group with no habit of tobacco and areca), Group II (control group with a habit of tobacco and areca), Group III (potentially malignant disorder-leukoplakia), and Group IV (oral squamous cell carcinoma (OSCC)). It was the first study to evaluate E2 in four study groups with and without the habit of tobacco.</p><p><strong>Method: </strong>The serum analysis was carried out in Cobas e411 analyzer by electrochemiluminescence immunoassay analysis.</p><p><strong>Results: </strong>As per the Kruskal--Wallis test, statistically significant rise in estradiol levels in Group IV as in comparison to Group III as compared with Groups II and I.</p><p><strong>Conclusion: </strong>This study proved that irrespective of the gender bias, the female sex hormone, estradiol levels were significantly raised in OSCC patients. This study suggests that E2 may play a vital role in determining the patient prognosis in OSCC with tobacco habit. The confounding results of this preliminary study opened up new advents emphasizing the role of E2 in OSCC. The role of E2 in estrogen receptor regulation can also be a subject of study for targeted therapies in improving the patient's prognosis.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":" ","pages":"1370-1375"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138815366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative evaluation of quality of life in oral cancer patients undergoing 3-dimensional conformal radiation therapy with or without concomitant chemotherapy - A longitudinal study. 对接受三维适形放疗并同时接受或不接受化疗的口腔癌患者生活质量的比较评估--一项纵向研究。
Pub Date : 2024-07-01 Epub Date: 2024-01-22 DOI: 10.4103/jcrt.jcrt_39_23
Prajakta M Parate, Aarti M Mahajan, Nilima Prakash, G L Pradeep, Shirin H Harnekar, Vaishali A Sadhwani

Objectives: To assess and compare the quality of life (QOL) in Oral Cancer patients undergoing 3-DCRT with or without concomitant Chemotherapy at three different time intervals.

Materials and methods: This unicentric longitudinal study included 50 patients of oral cancer undergoing 3-DCRT with or without concomitant chemotherapy. QOL was recorded using the EORTC H and N 35 Questionnaire at baseline, end of treatment (EOT), and 3 months after treatment.

Results: Maximum deterioration of most QOL domains were noted at End of treatment (EOT) in all the patients. A highly statistically significant difference was noted between different time intervals with the highest scores noted at the EOT ( P < 0.01). There was a statistically significant difference in patients undergoing 3DCRT with chemotherapy when compared to those with 3DCRT without chemotherapy ( P < 0.05).

Conclusion: There is substantial deterioration in QOL at the EOT after head-neck irradiation by 3-DCRT with or without concomitant Chemotherapy although it gradually improves over time. However, 3DCRT results in clinically meaningful and statistically better QOL scores at 3 months after treatment compared to baseline and EOT.

目的评估并比较口腔癌患者在三个不同时间间隔内接受 3-DCRT 并同时接受或不同时接受化疗的生活质量(QOL):这项单中心纵向研究包括 50 名接受或未接受 3-DCRT 化疗的口腔癌患者。在基线、治疗结束(EOT)和治疗后 3 个月使用 EORTC H 和 N 35 问卷记录 QOL:结果:在治疗结束(EOT)时,所有患者的大多数 QOL 领域都出现了最大程度的恶化。不同时间段之间的差异具有高度统计学意义,治疗结束时的得分最高(P < 0.01)。接受 3DCRT 化疗的患者与接受 3DCRT 非化疗的患者相比,差异有统计学意义(P < 0.05):结论:无论是否同时接受化疗,头颈部接受3-DCRT照射后,EOT时的生活质量都会大幅下降,但随着时间的推移会逐渐改善。然而,与基线和 EOT 相比,3-DCRT 治疗后 3 个月的 QOL 评分在临床上更有意义,在统计学上也更好。
{"title":"Comparative evaluation of quality of life in oral cancer patients undergoing 3-dimensional conformal radiation therapy with or without concomitant chemotherapy - A longitudinal study.","authors":"Prajakta M Parate, Aarti M Mahajan, Nilima Prakash, G L Pradeep, Shirin H Harnekar, Vaishali A Sadhwani","doi":"10.4103/jcrt.jcrt_39_23","DOIUrl":"10.4103/jcrt.jcrt_39_23","url":null,"abstract":"<p><strong>Objectives: </strong>To assess and compare the quality of life (QOL) in Oral Cancer patients undergoing 3-DCRT with or without concomitant Chemotherapy at three different time intervals.</p><p><strong>Materials and methods: </strong>This unicentric longitudinal study included 50 patients of oral cancer undergoing 3-DCRT with or without concomitant chemotherapy. QOL was recorded using the EORTC H and N 35 Questionnaire at baseline, end of treatment (EOT), and 3 months after treatment.</p><p><strong>Results: </strong>Maximum deterioration of most QOL domains were noted at End of treatment (EOT) in all the patients. A highly statistically significant difference was noted between different time intervals with the highest scores noted at the EOT ( P < 0.01). There was a statistically significant difference in patients undergoing 3DCRT with chemotherapy when compared to those with 3DCRT without chemotherapy ( P < 0.05).</p><p><strong>Conclusion: </strong>There is substantial deterioration in QOL at the EOT after head-neck irradiation by 3-DCRT with or without concomitant Chemotherapy although it gradually improves over time. However, 3DCRT results in clinically meaningful and statistically better QOL scores at 3 months after treatment compared to baseline and EOT.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":" ","pages":"1507-1511"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139543592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes with optimal treatment in geriatric head and neck cancers - Tertiary cancer centre experience. 老年头颈癌的最佳治疗效果--三级癌症中心的经验。
Pub Date : 2024-07-01 Epub Date: 2023-03-22 DOI: 10.4103/jcrt.jcrt_34_22
Imtiaz Ahmed, Sapna Krishnamurthy, Rohan Bhise, Kumar Vinchurkar, Mahesh Kalloli

Aim: Older patients with locally advanced head and neck cancers (LA-HNC) are under-represented in clinical trials and denied standard treatment with concurrent chemo-radiation. Most are treated with radiotherapy (RT) alone. However, with the use of Intensity Modulated Radiation Therapy (IMRT) and good supportive care, even this cohort of patients can be considered for chemo-radiation.

Methods and materials: 69 patients with age >65 years with LA-HNC treated between April 2015 and December 2019 in our Institute were prospectively evaluated for treatment compliance and outcomes. All patients were planned to receive 70 Gy in 33-35 fractions with IMRT and weekly Cisplatin at a dose of 40 mg/m2 (or Carboplatin-AUC-2). Loco-regional control (LRC), Overall survival (OS), and prognostic factors were evaluated.

Results: Median age at presentation was 67 years (65-81). 54 were male. 64% had Karnofsky Performance Status of >90. 42% had Oropharyngeal Primary. 17% had co-morbidities, 66% had T3 disease, 77% had Node positive disease, and 54% had Stage III disease. All patients completed 70 Gy and 81% patients received at least 5 (>200 mg/m2) chemotherapy cycles. Acute grade-3 toxicity was seen in 20% of patients and 64% had complete response. With a median follow up of 23.6 months (3-71), OS was 53.5%. Estimated 2-year LRC was 60%; estimated 2- and 5-year OS was 53.5% and 34.3%, respectively. On univariate analysis, age <70 years, Cisplatin use, limited nodal disease, Stage III, and complete response to treatment showed good OS (p < 0.05).

Conclusion: Definitive chemo-IMRT approach in older patients with LA-HNC is well tolerated with good clinical outcomes. Hence, older age should not be a barrier for standard treatment.

目的:患有局部晚期头颈部癌症(LA-HNC)的老年患者在临床试验中的比例较低,而且无法接受同期化疗和放疗的标准治疗。大多数患者只接受放射治疗(RT)。然而,随着调强放射治疗(IMRT)的使用和良好的支持性护理,即使是这部分患者也可以考虑接受化疗和放疗:对2015年4月至2019年12月期间在我院接受治疗的69例年龄大于65岁的LA-HNC患者的治疗依从性和疗效进行了前瞻性评估。所有患者均计划接受IMRT治疗,分33-35次,每次70 Gy,每周顺铂剂量为40 mg/m2(或卡铂-AUC-2)。对局部区域控制(LRC)、总生存期(OS)和预后因素进行了评估:中位发病年龄为67岁(65-81岁)。54人为男性。64%的患者 Karnofsky 表情大于 90。42%为口咽部原发性疾病。17%的患者有并发症,66%的患者病情为T3,77%的患者病情为结节阳性,54%的患者病情为III期。所有患者均完成了 70 Gy 化疗,81% 的患者接受了至少 5 个(>200 mg/m2)化疗周期。20%的患者出现急性3级毒性,64%的患者有完全反应。中位随访时间为23.6个月(3-71个月),OS为53.5%。估计2年LRC为60%;估计2年和5年OS分别为53.5%和34.3%。单变量分析显示,年龄年龄较大的 LA-HNC 患者对化疗-IMRT 的耐受性良好,临床疗效也很好。因此,年龄不应成为标准治疗的障碍。
{"title":"Outcomes with optimal treatment in geriatric head and neck cancers - Tertiary cancer centre experience.","authors":"Imtiaz Ahmed, Sapna Krishnamurthy, Rohan Bhise, Kumar Vinchurkar, Mahesh Kalloli","doi":"10.4103/jcrt.jcrt_34_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_34_22","url":null,"abstract":"<p><strong>Aim: </strong>Older patients with locally advanced head and neck cancers (LA-HNC) are under-represented in clinical trials and denied standard treatment with concurrent chemo-radiation. Most are treated with radiotherapy (RT) alone. However, with the use of Intensity Modulated Radiation Therapy (IMRT) and good supportive care, even this cohort of patients can be considered for chemo-radiation.</p><p><strong>Methods and materials: </strong>69 patients with age >65 years with LA-HNC treated between April 2015 and December 2019 in our Institute were prospectively evaluated for treatment compliance and outcomes. All patients were planned to receive 70 Gy in 33-35 fractions with IMRT and weekly Cisplatin at a dose of 40 mg/m2 (or Carboplatin-AUC-2). Loco-regional control (LRC), Overall survival (OS), and prognostic factors were evaluated.</p><p><strong>Results: </strong>Median age at presentation was 67 years (65-81). 54 were male. 64% had Karnofsky Performance Status of >90. 42% had Oropharyngeal Primary. 17% had co-morbidities, 66% had T3 disease, 77% had Node positive disease, and 54% had Stage III disease. All patients completed 70 Gy and 81% patients received at least 5 (>200 mg/m2) chemotherapy cycles. Acute grade-3 toxicity was seen in 20% of patients and 64% had complete response. With a median follow up of 23.6 months (3-71), OS was 53.5%. Estimated 2-year LRC was 60%; estimated 2- and 5-year OS was 53.5% and 34.3%, respectively. On univariate analysis, age <70 years, Cisplatin use, limited nodal disease, Stage III, and complete response to treatment showed good OS (p < 0.05).</p><p><strong>Conclusion: </strong>Definitive chemo-IMRT approach in older patients with LA-HNC is well tolerated with good clinical outcomes. Hence, older age should not be a barrier for standard treatment.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 5","pages":"1384-1389"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extensive metastatic ependymoma with long-term progression-free survival with capecitabine plus temozolomide combination chemotherapy: A case report. 卡培他滨加替莫唑胺联合化疗后,广泛转移性癫痫瘤获得长期无进展生存:病例报告。
Pub Date : 2024-07-01 Epub Date: 2023-05-03 DOI: 10.4103/jcrt.jcrt_1664_22
Engin Hendem, Mustafa Korkmaz, Murat Araz, Melek K Eryılmaz, Dilek Çağlayan, Seda T Ayçiçek, Buğra Kaya, Mehmet Artaç

Abstract: We wanted to present a rare case of metastatic grade 2 spinal ependymoma with an atypical course at the time of diagnosis. Temozolomide plus capecitabine chemotherapy was started in May 2018 on a 30-year-old female patient with sacral ependymoma who had extensive lung metastases at the time of diagnosis. The patient remained in remission for approximately 29 months, and the current chemotherapy was continued until it progressed in November 2020. According to this case report, a combination of temozolomide and capecitabine may be the best treatment option for ependymoma patients.

摘要:我们想介绍一例罕见的转移性2级脊柱外胚瘤病例,确诊时病程不典型。2018年5月,一名30岁的女性骶骨上皮瘤患者开始接受替莫唑胺加卡培他滨化疗,该患者在确诊时已有广泛的肺转移。该患者的病情持续缓解了约 29 个月,目前的化疗一直持续到 2020 年 11 月病情进展。根据这份病例报告,替莫唑胺和卡培他滨联合用药可能是脑外胚瘤患者的最佳治疗方案。
{"title":"Extensive metastatic ependymoma with long-term progression-free survival with capecitabine plus temozolomide combination chemotherapy: A case report.","authors":"Engin Hendem, Mustafa Korkmaz, Murat Araz, Melek K Eryılmaz, Dilek Çağlayan, Seda T Ayçiçek, Buğra Kaya, Mehmet Artaç","doi":"10.4103/jcrt.jcrt_1664_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1664_22","url":null,"abstract":"<p><strong>Abstract: </strong>We wanted to present a rare case of metastatic grade 2 spinal ependymoma with an atypical course at the time of diagnosis. Temozolomide plus capecitabine chemotherapy was started in May 2018 on a 30-year-old female patient with sacral ependymoma who had extensive lung metastases at the time of diagnosis. The patient remained in remission for approximately 29 months, and the current chemotherapy was continued until it progressed in November 2020. According to this case report, a combination of temozolomide and capecitabine may be the best treatment option for ependymoma patients.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 5","pages":"1625-1627"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mammary analogue secretory carcinoma involving submandibular gland: Diagnostic pitfall with review of literature. 累及颌下腺的乳腺类似物分泌性癌:诊断陷阱与文献综述。
Pub Date : 2024-07-01 Epub Date: 2024-09-19 DOI: 10.4103/jcrt.jcrt_2148_22
Nimisha Dhankar, Nidhi Verma, Abhinav Agarwal, Ravi Mehar, Sunil Pasricha

Abstract: Mammary analogue secretory carcinoma (MASC) is a recently defined entity among salivary gland tumors. MASC bores a striking resemblance to secretory carcinoma of breast along with the characteristics of ETV6-NTRK3 translocation. Hence, the entity was designated as MASC and was formally included in the 4th edition of World Health Organization classification of head and neck tumors in 2017. To the best of our knowledge, around 12 cases of MASC have been described in the Indian literature. MASC commonly involves parotid gland (70%). Involvement of submandibular gland is still rarer (7%). Prognosis of MASC is comparable to other low grade salivary gland malignancies; however, aggressive behavior has also been reported in few cases. This case is one of the very few reported cases describing MASC with detailed clinical, cytology, and microscopy findings along with special stains and immunohistochemistry.

摘要:乳腺类似分泌性癌(MASC)是最近定义的唾液腺肿瘤中的一种。MASC 与乳腺分泌性癌极为相似,同时具有 ETV6-NTRK3 易位的特征。因此,该实体被命名为MASC,并于2017年被正式纳入世界卫生组织第四版头颈部肿瘤分类。据我们所知,印度文献中描述了约12例MASC。MASC通常累及腮腺(70%)。累及颌下腺的病例仍较为罕见(7%)。MASC的预后与其他低度唾液腺恶性肿瘤相当,但也有少数病例报告其具有侵袭性。本病例是极少数报道的 MASC 病例之一,其中包括详细的临床、细胞学和显微镜检查结果,以及特殊染色和免疫组化。
{"title":"Mammary analogue secretory carcinoma involving submandibular gland: Diagnostic pitfall with review of literature.","authors":"Nimisha Dhankar, Nidhi Verma, Abhinav Agarwal, Ravi Mehar, Sunil Pasricha","doi":"10.4103/jcrt.jcrt_2148_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2148_22","url":null,"abstract":"<p><strong>Abstract: </strong>Mammary analogue secretory carcinoma (MASC) is a recently defined entity among salivary gland tumors. MASC bores a striking resemblance to secretory carcinoma of breast along with the characteristics of ETV6-NTRK3 translocation. Hence, the entity was designated as MASC and was formally included in the 4th edition of World Health Organization classification of head and neck tumors in 2017. To the best of our knowledge, around 12 cases of MASC have been described in the Indian literature. MASC commonly involves parotid gland (70%). Involvement of submandibular gland is still rarer (7%). Prognosis of MASC is comparable to other low grade salivary gland malignancies; however, aggressive behavior has also been reported in few cases. This case is one of the very few reported cases describing MASC with detailed clinical, cytology, and microscopy findings along with special stains and immunohistochemistry.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 5","pages":"1658-1661"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of bilateral superficial parotid gland sparing IMRT on xerostomia and QOL: A prospective study. 前瞻性研究: 双侧浅表腮腺切除 IMRT 对口腔溃疡和 QOL 的影响。
Pub Date : 2024-07-01 Epub Date: 2024-09-19 DOI: 10.4103/jcrt.jcrt_2072_22
Kanchan S Madhwapathy, Janaki Manur

Background: Superficial lobe constitutes 80% of the parotid and is situated lateral to mandible and can be better spared during intensity modulated radiation therapy (IMRT) for head and neck cancer (HNC). This study aimed to see the impact of bilateral superficial parotid gland (PG) sparing IMRT on xerostomia and quality of life (QOL) in patients with HNC receiving radiation.

Study design: Prospective, questionnaire-based study.

Materials and methods: Thirty-four patients with histopathologically proven non-nasopharyngeal non-oral cavity HNC were included in this study. IMRT technique was used and a constraint of 24 Gy was given to combined superficial PG. Physician- and patient-rated xerostomia and QOL scores were recorded at baseline and two weeks, three months, and six months post-radiation therapy (RT). The combined superficial PG dose correlated with xerostomia and QOL scores.

Results: The combined superficial PG and combined whole PG mean dose was 18.71 Gy and 30 Gy, respectively, and the difference was statistically significant (P-< 0.001). At two weeks, three months, and six months post-RT, the odds of xerostomia scores were 0.11, 0.071, 0.042, respectively for a median dose of <18 Gy compared to >18 Gy and was statistically significant P=(0.001).

Conclusion: Bilateral superficial PG sparing IMRT is beneficial in reducing xerostomia and translates to a better QOL.

背景:腮腺浅叶占腮腺的80%,位于下颌骨外侧,在头颈部癌症(HNC)的调强放射治疗(IMRT)中可以更好地保留腮腺浅叶。本研究旨在了解双侧浅表腮腺(PG)保留IMRT对接受放射治疗的HNC患者的口腔异味和生活质量(QOL)的影响:研究设计:前瞻性、基于问卷的研究:研究纳入了 34 名经组织病理学证实的非鼻咽非口腔 HNC 患者。采用IMRT技术,联合浅表PG的限制剂量为24 Gy。在基线、放射治疗(RT)后两周、三个月和六个月时,记录了医生和患者评定的口腔异味和 QOL 评分。表层 PG 联合剂量与口腔干燥和 QOL 评分相关:表层 PG 和整体 PG 的联合平均剂量分别为 18.71 Gy 和 30 Gy,差异有统计学意义(P-< 0.001)。RT术后两周、三个月和六个月,中位剂量为18 Gy时,口干评分的几率分别为0.11、0.071和0.042,差异有统计学意义(P=(0.001)):结论:双侧浅表PG疏散IMRT有利于减少口腔异味,并能改善患者的生活质量。
{"title":"Effect of bilateral superficial parotid gland sparing IMRT on xerostomia and QOL: A prospective study.","authors":"Kanchan S Madhwapathy, Janaki Manur","doi":"10.4103/jcrt.jcrt_2072_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2072_22","url":null,"abstract":"<p><strong>Background: </strong>Superficial lobe constitutes 80% of the parotid and is situated lateral to mandible and can be better spared during intensity modulated radiation therapy (IMRT) for head and neck cancer (HNC). This study aimed to see the impact of bilateral superficial parotid gland (PG) sparing IMRT on xerostomia and quality of life (QOL) in patients with HNC receiving radiation.</p><p><strong>Study design: </strong>Prospective, questionnaire-based study.</p><p><strong>Materials and methods: </strong>Thirty-four patients with histopathologically proven non-nasopharyngeal non-oral cavity HNC were included in this study. IMRT technique was used and a constraint of 24 Gy was given to combined superficial PG. Physician- and patient-rated xerostomia and QOL scores were recorded at baseline and two weeks, three months, and six months post-radiation therapy (RT). The combined superficial PG dose correlated with xerostomia and QOL scores.</p><p><strong>Results: </strong>The combined superficial PG and combined whole PG mean dose was 18.71 Gy and 30 Gy, respectively, and the difference was statistically significant (P-< 0.001). At two weeks, three months, and six months post-RT, the odds of xerostomia scores were 0.11, 0.071, 0.042, respectively for a median dose of <18 Gy compared to >18 Gy and was statistically significant P=(0.001).</p><p><strong>Conclusion: </strong>Bilateral superficial PG sparing IMRT is beneficial in reducing xerostomia and translates to a better QOL.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 5","pages":"1400-1405"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of radiation dose rates and cisplatin on cytogenetic damage in rats receiving head-neck radiotherapy. 辐射剂量率和顺铂对接受头颈部放疗大鼠细胞遗传损伤的影响
Pub Date : 2024-07-01 Epub Date: 2023-04-05 DOI: 10.4103/jcrt.jcrt_2006_22
Dilek Unal, Aslihan Kiraz, Serhat Aydogan, Zeynep Soyer Sarica, Harun Celik, Ebru Akay, Celalettin Eroglu, Bunyamin Kaplan

Background: We aimed to investigate effect of radiotherapy (RT) applications with different dose rates on cytogenetic damages, which focused on micronucleus (MN) formation, and evaluate how this damage varies by cisplatin in rats receiving head-neck RT.

Material and methods: Thirty-six Sprague Dawley rats were divided into five groups. The first and second groups were irradiated at a dose rate of 300 monitor unit/minute (MU/min) and 600 MU/min, respectively. The third group was irradiated at a dose rate of 300 MU/min and given cisplatin. The fourth group was irradiated at a dose rate of 600 MU/min and given cisplatin. The fifth group received neither irradiation nor cisplatin (control group). One thousand polychromatic erythrocytes were scored, and MN frequency in polychromatic erythrocytes was determined for each rat.

Results: There was a significant difference among five groups in terms of the number of MN (p: 0.001). The number of MN was significantly higher in the 600 MU/min + cisplatin group (fourth group) compared to the control group [9.5 (1.0-23.0) vs. 1.5 (1.0-2.0), respectively]. It was also significantly higher in 600 MU/min + cisplatin group (fourth group) compared to 300 MU/min group (first group) [9.5 (1.0-23.0) vs. 2.0 (1.0-3.0), respectively]. On the other hand, there was no significant difference among other groups.

Conclusions: Our findings suggest that RT given at a higher dose rate causes more cytogenetic damage, and this damage is increased by concurrent administration of cisplatin.

背景:我们的目的是研究不同剂量率的放射治疗(RT)对细胞遗传学损伤的影响,重点是微核(MN)的形成,并评估顺铂对接受头颈部RT的大鼠的损伤有何影响:将 36 只 Sprague Dawley 大鼠分为五组。第一组和第二组分别以 300 个监测单位/分钟(MU/min)和 600 个监测单位/分钟的剂量率进行照射。第三组以 300 MU/min 的剂量率进行照射,并给予顺铂。第四组以 600 MU/min 的剂量率进行照射,并给予顺铂。第五组既不接受辐照,也不服用顺铂(对照组)。对每只大鼠的一千个多色红细胞进行评分,并测定多色红细胞中的 MN 频率:结果:五组大鼠的 MN 数量存在明显差异(P:0.001)。与对照组相比,600 MU/min + 顺铂组(第四组)的 MN 数量明显增加[分别为 9.5 (1.0-23.0) vs. 1.5 (1.0-2.0)]。与 300 MU/min 组(第一组)相比,600 MU/min + 顺铂组(第四组)的死亡率也明显更高[分别为 9.5 (1.0-23.0) vs. 2.0 (1.0-3.0)]。结论:我们的研究结果表明,较高剂量率的 RT 会导致更多的细胞遗传学损伤,而同时使用顺铂会加重这种损伤。
{"title":"Effect of radiation dose rates and cisplatin on cytogenetic damage in rats receiving head-neck radiotherapy.","authors":"Dilek Unal, Aslihan Kiraz, Serhat Aydogan, Zeynep Soyer Sarica, Harun Celik, Ebru Akay, Celalettin Eroglu, Bunyamin Kaplan","doi":"10.4103/jcrt.jcrt_2006_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2006_22","url":null,"abstract":"<p><strong>Background: </strong>We aimed to investigate effect of radiotherapy (RT) applications with different dose rates on cytogenetic damages, which focused on micronucleus (MN) formation, and evaluate how this damage varies by cisplatin in rats receiving head-neck RT.</p><p><strong>Material and methods: </strong>Thirty-six Sprague Dawley rats were divided into five groups. The first and second groups were irradiated at a dose rate of 300 monitor unit/minute (MU/min) and 600 MU/min, respectively. The third group was irradiated at a dose rate of 300 MU/min and given cisplatin. The fourth group was irradiated at a dose rate of 600 MU/min and given cisplatin. The fifth group received neither irradiation nor cisplatin (control group). One thousand polychromatic erythrocytes were scored, and MN frequency in polychromatic erythrocytes was determined for each rat.</p><p><strong>Results: </strong>There was a significant difference among five groups in terms of the number of MN (p: 0.001). The number of MN was significantly higher in the 600 MU/min + cisplatin group (fourth group) compared to the control group [9.5 (1.0-23.0) vs. 1.5 (1.0-2.0), respectively]. It was also significantly higher in 600 MU/min + cisplatin group (fourth group) compared to 300 MU/min group (first group) [9.5 (1.0-23.0) vs. 2.0 (1.0-3.0), respectively]. On the other hand, there was no significant difference among other groups.</p><p><strong>Conclusions: </strong>Our findings suggest that RT given at a higher dose rate causes more cytogenetic damage, and this damage is increased by concurrent administration of cisplatin.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 5","pages":"1595-1598"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pilot study of radiation oncology peer review in low middle income country (LMIC) through cloud-based platform. 通过云平台在中低收入国家(LMIC)开展放射肿瘤同行评审试点研究。
Pub Date : 2024-07-01 Epub Date: 2024-09-19 DOI: 10.4103/jcrt.jcrt_1697_23
Manjinder S Sidhu, Garima Gokhroo, Suneetha Mulinti, Mangesh B Pati, Midhun Murali, Vibhor Gupta, Suresh Chaudhari, Kareem Rayn, Sushil Beriwal

Purpose: Peer review is an essential step in clinical quality assurance for radiation therapy. There are very little data on peer reviews from low-middle-income countries (LMIC). With increasing access to advanced technologies in LMIC also, peer review is becoming more important to ensure quality and standard of care. We evaluated cloud-based e-Peer review in our network of cancer centers in India with an aim to study its feasibility and impact on care.

Materials and methods: Four out of 13 cancer centers across India were selected for this pilot study. All team members were trained on the e-Peer review platform before the initiation of the study. A lead dosimetrist from a centralized planning site was selected to share new cases every week. Cases treated with only definitive intent were selected. The link to the cases was sent through an email to reviewing physicians. The following aspects were reviewed for each case. 1) Work up and staging. 2) Treatment intent and prescription. 3) Target contours. 4) Normal organ at risk contours. 5) Dose-volume-histogram (DVH) with clinical goals attached. Cases were marked as "Not Appropriate," "Appropriate," "Appropriate with minor finding," and "Represent with major revisions" as per volume and plan review.

Results: Over a period of 3 months, 100 cases underwent peer review before the start of treatment. Median turnover time was 48 (interquartile range: 24-96) hours. The median time for review was 8 min with time to review cases requiring major and minor changes being 12 and 6 min, respectively (P < 0.001). Of all the cases reviewed, no changes, minor changes, and major changes were suggested for 36%, 48%, and 16% of cases, respectively. The most frequent reason for major changes was contouring corrections (15%). Also, 31.3% of major changes underwent recontouring and replanning before initiation of treatment.

Conclusion: Peer review was feasible in our setting through this cloud-based peer review system, with median turnover time and time taken for review being 48 h and 8 min, respectively. Like published data from the Western world, peer review led to changes that could impact patient care delivery and outcome. We plan to implement this across the remaining centers in our network.

目的:同行评审是放射治疗临床质量保证的重要步骤。中低收入国家(LMIC)的同行评审数据非常少。随着中低收入国家越来越多地使用先进技术,同行评审对于确保医疗质量和标准也变得越来越重要。我们在印度的癌症中心网络中对基于云的电子同行评审进行了评估,旨在研究其可行性和对护理的影响:在印度的 13 家癌症中心中选择了四家进行试点研究。研究开始前,所有团队成员都接受了电子同行评审平台的培训。从一个集中规划点选出一名主要剂量测定师,每周分享新病例。所选病例仅为确诊治疗病例。病例链接通过电子邮件发送给审查医生。对每个病例进行以下方面的审查。1) 检查和分期。2) 治疗意图和处方。3) 目标轮廓。4) 有风险的正常器官轮廓。5) 附有临床目标的剂量-容量-组图(DVH)。根据数量和计划审查结果,病例被标记为 "不合适"、"合适"、"合适但有小的发现 "和 "有重大修改的代表":在 3 个月的时间里,有 100 个病例在治疗开始前接受了同行评审。周转时间中位数为 48 小时(四分位间范围:24-96 小时)。审查时间的中位数为 8 分钟,需要进行重大和轻微修改的病例审查时间分别为 12 分钟和 6 分钟(P < 0.001)。在所有复查病例中,建议不作修改、作小修改和作大修改的病例分别占 36%、48% 和 16%。主要修改的最常见原因是轮廓修正(15%)。此外,31.3%的重大改动在开始治疗前进行了重新塑形和重新规划:结论:通过基于云的同行评审系统进行同行评审在我们这里是可行的,中位周转时间和评审时间分别为 48 小时和 8 分钟。与西方国家已公布的数据一样,同行评审带来的改变可能会影响患者的治疗效果。我们计划在我们网络中的其余中心实施这一系统。
{"title":"Pilot study of radiation oncology peer review in low middle income country (LMIC) through cloud-based platform.","authors":"Manjinder S Sidhu, Garima Gokhroo, Suneetha Mulinti, Mangesh B Pati, Midhun Murali, Vibhor Gupta, Suresh Chaudhari, Kareem Rayn, Sushil Beriwal","doi":"10.4103/jcrt.jcrt_1697_23","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1697_23","url":null,"abstract":"<p><strong>Purpose: </strong>Peer review is an essential step in clinical quality assurance for radiation therapy. There are very little data on peer reviews from low-middle-income countries (LMIC). With increasing access to advanced technologies in LMIC also, peer review is becoming more important to ensure quality and standard of care. We evaluated cloud-based e-Peer review in our network of cancer centers in India with an aim to study its feasibility and impact on care.</p><p><strong>Materials and methods: </strong>Four out of 13 cancer centers across India were selected for this pilot study. All team members were trained on the e-Peer review platform before the initiation of the study. A lead dosimetrist from a centralized planning site was selected to share new cases every week. Cases treated with only definitive intent were selected. The link to the cases was sent through an email to reviewing physicians. The following aspects were reviewed for each case. 1) Work up and staging. 2) Treatment intent and prescription. 3) Target contours. 4) Normal organ at risk contours. 5) Dose-volume-histogram (DVH) with clinical goals attached. Cases were marked as \"Not Appropriate,\" \"Appropriate,\" \"Appropriate with minor finding,\" and \"Represent with major revisions\" as per volume and plan review.</p><p><strong>Results: </strong>Over a period of 3 months, 100 cases underwent peer review before the start of treatment. Median turnover time was 48 (interquartile range: 24-96) hours. The median time for review was 8 min with time to review cases requiring major and minor changes being 12 and 6 min, respectively (P < 0.001). Of all the cases reviewed, no changes, minor changes, and major changes were suggested for 36%, 48%, and 16% of cases, respectively. The most frequent reason for major changes was contouring corrections (15%). Also, 31.3% of major changes underwent recontouring and replanning before initiation of treatment.</p><p><strong>Conclusion: </strong>Peer review was feasible in our setting through this cloud-based peer review system, with median turnover time and time taken for review being 48 h and 8 min, respectively. Like published data from the Western world, peer review led to changes that could impact patient care delivery and outcome. We plan to implement this across the remaining centers in our network.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 5","pages":"1591-1594"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study of non-invasive follicular thyroid neoplasm: A borderline entity. 非侵袭性甲状腺滤泡性肿瘤的研究:一个边缘实体。
Pub Date : 2024-07-01 Epub Date: 2024-09-19 DOI: 10.4103/jcrt.jcrt_2327_22
Rupali Bavikar, Ruchi S Randive, Anubhaw Verma, Madhuri Singh, Vidya Viswanathan, Arpana Dharwadkar

Background: Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is a newly added entity in the fourth edition of the WHO Classification of Tumors of Endocrine Organs (2017). It is regarded as a neoplasm with very low malignant potential, thus affecting further treatment of the patients.

Aims: To study the recently diagnosed entity, NIFTP, as not many cases have been reported of the same.

Materials and methods: A retrospective analysis of all thyroid neoplasms received in the Department of Pathology of our institute over two years was done. Out of the 188 cases that we reported, 38 were of non-invasive follicular neoplasms.

Results: Thirty-two patients were female, whereas six patients were male. Thirty-five patients presented with solitary thyroid nodule and the others had an ill-defined thyroid swelling. Thirty-four patients had normal thyroid profile while two patients each presented with hypothyroidism and hyperthyroidism.

Conclusion: It is crucial to carefully study the histopathological features of solitary thyroid swellings and correlate with clinical and radiological findings. The recently added diagnostic category of NIFTP helps clinicians prevent over-treatment of a group of low-risk thyroid tumors.

背景:具有乳头状核特征的非侵袭性甲状腺滤泡性肿瘤(NIFTP)是第四版《世界卫生组织内分泌器官肿瘤分类》(2017年)中新增的一种肿瘤。它被认为是一种恶性潜能极低的肿瘤,因此影响了患者的进一步治疗。目的:研究最近诊断出的实体肿瘤--NIFTP,因为关于该实体肿瘤的病例报道并不多。材料与方法:对所有甲状腺肿瘤进行回顾性分析:对我院病理科两年来接诊的所有甲状腺肿瘤进行回顾性分析。在我们报告的 188 例病例中,38 例为非侵袭性滤泡性肿瘤:结果:32 名患者为女性,6 名患者为男性。35例患者表现为单发甲状腺结节,其他患者的甲状腺肿大不明确。34例患者甲状腺功能正常,甲状腺功能减退和甲状腺功能亢进患者各2例:结论:仔细研究单发性甲状腺肿的组织病理学特征并与临床和放射学检查结果进行关联至关重要。最近新增的NIFTP诊断类别有助于临床医生防止对这类低风险甲状腺肿瘤进行过度治疗。
{"title":"Study of non-invasive follicular thyroid neoplasm: A borderline entity.","authors":"Rupali Bavikar, Ruchi S Randive, Anubhaw Verma, Madhuri Singh, Vidya Viswanathan, Arpana Dharwadkar","doi":"10.4103/jcrt.jcrt_2327_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2327_22","url":null,"abstract":"<p><strong>Background: </strong>Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is a newly added entity in the fourth edition of the WHO Classification of Tumors of Endocrine Organs (2017). It is regarded as a neoplasm with very low malignant potential, thus affecting further treatment of the patients.</p><p><strong>Aims: </strong>To study the recently diagnosed entity, NIFTP, as not many cases have been reported of the same.</p><p><strong>Materials and methods: </strong>A retrospective analysis of all thyroid neoplasms received in the Department of Pathology of our institute over two years was done. Out of the 188 cases that we reported, 38 were of non-invasive follicular neoplasms.</p><p><strong>Results: </strong>Thirty-two patients were female, whereas six patients were male. Thirty-five patients presented with solitary thyroid nodule and the others had an ill-defined thyroid swelling. Thirty-four patients had normal thyroid profile while two patients each presented with hypothyroidism and hyperthyroidism.</p><p><strong>Conclusion: </strong>It is crucial to carefully study the histopathological features of solitary thyroid swellings and correlate with clinical and radiological findings. The recently added diagnostic category of NIFTP helps clinicians prevent over-treatment of a group of low-risk thyroid tumors.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"20 5","pages":"1365-1369"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of cancer research and therapeutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1